Epclusa Umoja wa Ulaya - Kinorwe - EMA (European Medicines Agency)

epclusa

gilead sciences ireland uc - sofosbuvir, velpatasvir - hepatitt c, kronisk - antivirale midler til systemisk bruk - epclusa is indicated for the treatment of chronic hepatitis c virus (hcv) infection in patients 3 years of age and older (see sections 4. 2, 4. 4 og 5.

Harvoni Umoja wa Ulaya - Kinorwe - EMA (European Medicines Agency)

harvoni

gilead sciences ireland uc - ledipasvir, sofosbuvir - hepatitt c, kronisk - antivirale midler til systemisk bruk - harvoni is indicated for the treatment of chronic hepatitis c (chc) in adult and paediatric patients aged 3 years and above (see sections 4. 2, 4. 4 og 5. for hepatitt c-virus (hcv) genotype-spesifikk aktivitet, se kapittel 4. 4 og 5.

Orfiril long 500 mg Norwe - Kinorwe - Statens legemiddelverk

orfiril long 500 mg

desitin arzneimittel gmbh - natriumvalproat - depotgranulat - 500 mg

Orfiril long 1000 mg Norwe - Kinorwe - Statens legemiddelverk

orfiril long 1000 mg

desitin arzneimittel gmbh - natriumvalproat - depotgranulat - 1000 mg

Orfiril long 150 mg Norwe - Kinorwe - Statens legemiddelverk

orfiril long 150 mg

desitin arzneimittel gmbh - natriumvalproat - depotkapsel, hard - 150 mg

Orfiril long 300 mg Norwe - Kinorwe - Statens legemiddelverk

orfiril long 300 mg

desitin arzneimittel gmbh - natriumvalproat - depotkapsel, hard - 300 mg

Orfiril 100 mg/ ml Norwe - Kinorwe - Statens legemiddelverk

orfiril 100 mg/ ml

desitin arzneimittel gmbh - natriumvalproat - injeksjonsvæske, oppløsning - 100 mg/ ml

Orfiril 60 mg/ ml Norwe - Kinorwe - Statens legemiddelverk

orfiril 60 mg/ ml

desitin arzneimittel gmbh - natriumvalproat - mikstur, oppløsning - 60 mg/ ml

Orfiril retard 300 mg Norwe - Kinorwe - Statens legemiddelverk

orfiril retard 300 mg

desitin arzneimittel gmbh - natriumvalproat - depottablett - 300 mg

Vosevi Umoja wa Ulaya - Kinorwe - EMA (European Medicines Agency)

vosevi

gilead sciences ireland uc - sofosbuvir, velpatasvir, voxilaprevi - hepatitt c, kronisk - antivirale midler til systemisk bruk - vosevi is indicated for the treatment of chronic hepatitis c virus (hcv) infection in patients aged 12 years and older and weighing at least 30 kg. (se kapittel 4. 2, 4. 4 og 5.